These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 27764715)

  • 21. Maintenance of immune hyporesponsiveness to melanosomal proteins by DHICA-mediated antioxidation: Possible implications for autoimmune vitiligo.
    Liu XM; Zhou Q; Xu SZ; Wakamatsu K; Lei TC
    Free Radic Biol Med; 2011 May; 50(9):1177-85. PubMed ID: 21256957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Misbalanced CXCL12 and CCL5 Chemotactic Signals in Vitiligo Onset and Progression.
    Rezk AF; Kemp DM; El-Domyati M; El-Din WH; Lee JB; Uitto J; Igoucheva O; Alexeev V
    J Invest Dermatol; 2017 May; 137(5):1126-1134. PubMed ID: 28132854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autoimmune aspects of vitiligo.
    Kemp EH; Waterman EA; Weetman AP
    Autoimmunity; 2001; 34(1):65-77. PubMed ID: 11681494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physiopathology and genetics of vitiligo.
    Passeron T; Ortonne JP
    J Autoimmun; 2005; 25 Suppl():63-8. PubMed ID: 16298511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the elevated IFN-γ in vitiligo patients by human anti- IFN-γ monoclonal antibody hampers direct cytotoxicity in melanocyte.
    Ng CY; Chan YP; Chiu YC; Shih HP; Lin YN; Chung PH; Huang JY; Chen HK; Chung WH; Ku CL
    J Dermatol Sci; 2023 Jun; 110(3):78-88. PubMed ID: 37221109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD4 T cell-dependent autoimmunity against a melanocyte neoantigen induces spontaneous vitiligo and depends upon Fas-Fas ligand interactions.
    Lambe T; Leung JC; Bouriez-Jones T; Silver K; Makinen K; Crockford TL; Ferry H; Forrester JV; Cornall RJ
    J Immunol; 2006 Sep; 177(5):3055-62. PubMed ID: 16920942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vitiligo Pathogenesis and Emerging Treatments.
    Rashighi M; Harris JE
    Dermatol Clin; 2017 Apr; 35(2):257-265. PubMed ID: 28317534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autoimmune etiology of generalized vitiligo.
    Le Poole IC; Luiten RM
    Curr Dir Autoimmun; 2008; 10():227-43. PubMed ID: 18460889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced Th1 and Th17 responses in peripheral blood in active non-segmental vitiligo.
    Zhen Y; Yao L; Zhong S; Song Y; Cui Y; Li S
    Arch Dermatol Res; 2016 Dec; 308(10):703-710. PubMed ID: 27687555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitiligo.
    Picardo M; Dell'Anna ML; Ezzedine K; Hamzavi I; Harris JE; Parsad D; Taieb A
    Nat Rev Dis Primers; 2015 Jun; 1():15011. PubMed ID: 27189851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perspectives of New Advances in the Pathogenesis of Vitiligo: From Oxidative Stress to Autoimmunity.
    Wang Y; Li S; Li C
    Med Sci Monit; 2019 Feb; 25():1017-1023. PubMed ID: 30723188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding autoimmunity of vitiligo and alopecia areata.
    Rork JF; Rashighi M; Harris JE
    Curr Opin Pediatr; 2016 Aug; 28(4):463-9. PubMed ID: 27191524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Research progress of vitiligo repigmentation: from oxidative stress to autoimmunity.
    Yu T; Wu Y; Lu Z
    Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):147-151. PubMed ID: 38678613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current remedies for vitiligo.
    Abu Tahir M; Pramod K; Ansari SH; Ali J
    Autoimmun Rev; 2010 May; 9(7):516-20. PubMed ID: 20149899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunopathogenesis of vitiligo.
    Sandoval-Cruz M; García-Carrasco M; Sánchez-Porras R; Mendoza-Pinto C; Jiménez-Hernández M; Munguía-Realpozo P; Ruiz-Argüelles A
    Autoimmun Rev; 2011 Oct; 10(12):762-5. PubMed ID: 21334464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of Memory CD8
    Riding RL; Harris JE
    J Immunol; 2019 Jul; 203(1):11-19. PubMed ID: 31209143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The enigma and challenges of vitiligo pathophysiology and treatment.
    Abdel-Malek ZA; Jordan C; Ho T; Upadhyay PR; Fleischer A; Hamzavi I
    Pigment Cell Melanoma Res; 2020 Nov; 33(6):778-787. PubMed ID: 32198977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Innate immune mechanisms in vitiligo: danger from within.
    Richmond JM; Frisoli ML; Harris JE
    Curr Opin Immunol; 2013 Dec; 25(6):676-82. PubMed ID: 24238922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular and cellular basis of depigmentation in vitiligo patients.
    Delmas V; Larue L
    Exp Dermatol; 2019 Jun; 28(6):662-666. PubMed ID: 30536790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vitiligo: How do oxidative stress-induced autoantigens trigger autoimmunity?
    Xie H; Zhou F; Liu L; Zhu G; Li Q; Li C; Gao T
    J Dermatol Sci; 2016 Jan; 81(1):3-9. PubMed ID: 26387449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.